According to Zhitong Finance App News, Columbotai Biotech (06990.HK) announced a number of clinical research results at the 2026 European Society of Medical Oncology (ESMO) conference held in Madrid, Spain from October 23 to 27, covering data related to the targeting human trophic cell surface antigen 2 (TROP2) antibody conjugate drug (ADC) lucansatuzumab (sac TMT) (Cathay Lai®) and ADC SKB500 targeting B7-H3.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.